Raptor Pharmaceutical Receives Marketing Authorization for PROCYSBI(R) in European Union
12 sept. 2013 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the European Commission (EC) has approved PROCYSBI® gastro-resistant hard...
Raptor Pharmaceutical Announces Presentation at the International Pediatric Nephrology Association Meeting in Shanghai
29 août 2013 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI (cysteamine bitartrate) will be featured in an upcoming presentation at the...
Raptor Pharmaceutical Provides PROCYSBI(TM) Launch Update and Second Quarter 2013 Financial Results
08 août 2013 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided a launch update for PROCYSBI (cysteamine bitartrate) delayed-release capsules and financial...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
06 août 2013 07h29 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, Raptor's Executive Vice President, Strategy and Chief Operating...
Raptor Pharmaceutical to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 8, 2013
01 août 2013 07h29 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2013 financial results after market close on Thursday,...
PROCYSBI(R) Receives Positive Opinion for Orphan Drug Exclusivity From the EU Committee for Orphan Medicinal Products
22 juil. 2013 07h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has received a positive opinion from the European Union (EU) Committee for Orphan...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
02 juil. 2013 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's CEO, will present an overview of the company at...
Raptor's PROCYSBI(TM) Receives U.S. Orphan Drug Exclusivity
25 juin 2013 16h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the Office of Orphan Product Development at the Food and Drug Administration (FDA)...
Raptor's PROCYSBI(TM) Now Commercially Available in the U.S. for Nephropathic Cystinosis Patients
19 juin 2013 07h00 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI™ (cysteamine bitartrate) delayed-release capsules are now available in...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
12 juin 2013 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of...